WeVote
Log In

Bill

Bill

S 1415

Establishes the bullet-proof vests for officers fund

2025 Regular Session Introduced by Jim Tedisco

The bill requires DMH and DESE to study whether neuroimmune conditions like PANDAS/PANS are missed in pediatric psychiatric facilities and therapeutic schools, and report findings.

REFERRED TO FINANCE
0
WeVote Research Nonpartisan
Bill Summary · S 1415

Bill Summary — S 1415 (2025)

Note: The bill text provided focuses on PANDAS/PANS. Some accompanying metadata (title referencing bullet‑proof vests and lists of federal sponsors) appears to conflict with the bill text and Massachusetts docket information. This summary is based on the bill text uploaded (An Act relative to PANDAS/PANS) and the procedural entries tied to that text.

Purpose

Require the Massachusetts Department of Mental Health (DMH), in conjunction with the Department of Elementary and Secondary Education (DESE), to study whether children in pediatric/adolescent psychiatric hospitals and therapeutic day schools have underlying neuroimmune conditions—specifically pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute‑onset neuropsychiatric syndrome (PANS)—that were missed or previously misdiagnosed.

Key provisions

  • Scope: A state‑directed study of pediatric and adolescent psychiatric hospital settings and therapeutic day schools to identify possible root causes tied to neuroimmune issues, PANDAS, and PANS.
  • Standards: DMH and DESE must use established clinical criteria developed by the PANS/PANDAS Consortium (available through the PANDAS Physicians Network) and consult other relevant experts.
  • Interviews & consultation:
    • Interview children and families who were previously misdiagnosed but later identified as having PANDAS/PANS while they were accessing DMH supports.
    • Consult the Department of Public Health’s PANDAS/PANS Advisory Council and professionals working in the specified treatment/education settings.
  • Required findings: At minimum the study must:
    • Estimate the prevalence of PANDAS/PANS in the covered psychiatric hospitals and therapeutic day schools.
    • Report outcomes for interviewed children and families who were previously misdiagnosed and later found to have PANDAS/PANS.
  • Reporting deadline: DMH and DESE must submit the study findings by December 31, 2026 to:
    • Joint Committee on Public Health
    • Joint Committee on Mental Health and Substance Use and Recovery
    • Department of Public Health
    • PANDAS/PANS Advisory Council
    • Clerk of the Senate and Clerk of the House

Who would be affected

  • Children and adolescents in psychiatric hospital settings and therapeutic day schools in Massachusetts.
  • Families of those children (particularly those with prior misdiagnosis).
  • State agencies: DMH, DESE, and Department of Public Health.
  • Clinical providers and school/treatment professionals who diagnose or treat pediatric neuropsychiatric conditions.
  • PANDAS/PANS Advisory Council and clinical experts consulted.

Procedural and timeline notes

  • Introduced: April 10, 2025 (Senate docket No. 341 in the Massachusetts General Court).
  • Status entries (as provided) include referrals to multiple committees (Mental Health/Substance Use and Recovery; Finance; Banking, Housing, and Urban Affairs; Health Care Financing) and a reported favorable committee reference on 2025‑11‑06. A hearing was scheduled for 06/30/2025. (Metadata contains some duplicated/conflicting entries.)
  • Report/reporting deadline: Final study report due December 31, 2026.

Related legislation

  • Companion/related entries listed include HR 965, SD 341, A 2628 and several prior‑session bills (e.g., S 4429, S 1152, S 1527, S 906).

Observations/considerations

  • The bill mandates a study but does not provide specific funding or appropriations in the text provided; implementation may require resources or interagency coordination.
  • Use of established PANS/PANDAS clinical criteria and engagement with the DPH Advisory Council suggests the study aims both to measure prevalence and to inform policy/clinical practice changes if underdiagnosis is documented.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.